Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study-Reference-Cited by-同舟云学术

Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study

Published:2023-07-08 Issue: Volume: Page:
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Kogan Lawrence¹,Townsend Matthew J²,Raj Dhanya³,Levy Alexander N⁴,Giobbie-Hurder Anita⁵,Grover Shilpa³⁶^ORCID

Affiliation:

1. Division of Digestive Diseases, Yale School of Medicine , New Haven, CT , USA

2. Department of Medicine, Duke University Medical Center , Durham, NC , USA

3. Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women’s Hospital , Boston, MA , USA

4. Division of Gastroenterology, Tufts Medical Center , Boston, MA , USA

5. Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute , Boston, MA , USA

6. Harvard Medical School , Boston, MA , USA

Abstract

Lay Summary In the emerging field of immune checkpoint inhibitor enterocolitis, biomarkers to predict disease course are lacking. Select genetic polymorphisms (ATG16L1T300A) and serum amyloid A warrant further study as potential biomarkers associated with severe ICI enterocolitis.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izad121/50842930/izad121.pdf

Reference10 articles.

1. Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease;Thomas;Clin Gastroenterol Hepatol.,2022

2. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn’s disease, and ulcerative colitis patients;Plevy;Inflamm Bowel Dis.,2013

3. Biomarkers of Crohn’s disease to support the development of new therapeutic interventions;Porter;Inflamm Bowel Dis.,2020

4. C-reactive protein as an early marker of immune-related adverse events;Abolhassani;J Cancer Res Clin Oncol.,2019

5. Immune checkpoint inhibitor-associated colitis: from mechanism to management;Tang;Front Immunol.,2021